, based in Leverkusen , Germany , researches , manufactures and markets pharmaceutical products . Bayer promotes One A Day Men 's 50 + Advantage and One A Day Men 's Health Formula multivitamins on package labels , TV and radio ads and on its Web site . In its promotions , the company says `` emerging research '' suggests that selenium might reduce the risk of prostate cancer , the center said . `` Did you know that there are more new cases of prostate cancer each year than any other cancer ? '' according to one radio ad . `` Now there is something you can do . '' Both dietary supplements contain 105 micrograms of the trace mineral selenium per daily dose , or about twice the Recommended Daily Allowance , which is 55 micrograms a day for adults , according to the center . Visit CNNhealth.com , your connection for better living `` It 's astounding that a company such as Bayer ... would make such deceptive claims , '' the center 's litigation director , Steve Gardner , told reporters during the same teleconference . Supporting the center in its letter of complaint to the
WASHINGTON -LRB- CNN -RRB- -- A nonprofit consumer group said Thursday that it will sue Bayer HealthCare , alleging `` deceptive and irresponsible '' advertising that contends selenium in two of its multivitamins may reduce men 's risk of prostate cancer . One A Day Men 's 50 + Advantage ads say selenium may cut men 's risk of prostate cancer , a consumer group says . The Center for Science in the Public Interest said it informed the multinational company of its intent Thursday . David Schardt , the center 's senior nutritionist , told reporters during a teleconference that the center already has filed a complaint with the Federal Trade Commission . `` We are standing behind all the claims we make in support of the products , '' Trish McKernan , Bayer 's global spokeswoman , told CNN . `` The selenium claims are made by a -LSB- Food and Drug Administration -RSB- - approved qualified health claim . We regularly review the evidence , and we change our claims if necessitated . The emerging science has n't compelled us to change our claims , and the FDA claim is intact . '' Bayer 's HealthCare division